Review anchor
Peroxisome proliferator-activated receptor alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Peroxisome proliferator-activated receptor alpha
CHEMBL239
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peroxisome proliferator-activated receptor alpha as ChEMBL target CHEMBL239, mapped to UniProt Q07869. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL239
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q07869
Peroxisome proliferator-activated receptor alpha
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Peroxisome proliferator-activated receptor alpha matters
Peroxisome proliferator-activated receptor alpha is reviewed as Peroxisome proliferator-activated receptor alpha (UniProt Q07869); Peroxisome proliferator-activated receptor alpha shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded.; the current evidence base includes 15 approved drugs, 5004 compounds, and 1100 assays, with lead potency reaching pChEMBL 10.6.
Protein context
Peroxisome proliferator-activated receptor alpha
Peroxisome proliferator-activated receptor alpha Sequence length is 468 aa.
Review this target as Peroxisome proliferator-activated receptor alpha, mapped to UniProt Q07869. Sequence length is 468 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q07869
Protein
Disease context
type 2 diabetes mellitus
Peroxisome proliferator-activated receptor alpha shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALEGLITAZAR, ELAFIBRANOR, FENOFIBRATE.
Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALEGLITAZAR, ELAFIBRANOR, FENOFIBRATE, FENOFIBRIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
9 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 15 approved drugs, 5004 compounds, and 1100 assays for this target. The dominant activity type is EC50. CHEMBL1813003 is the current potency anchor at pChEMBL 10.6.
Use CHEMBL1813003 as the tractability anchor when discussing potency (pChEMBL 10.6).
Activity source · ChEMBL 36 via Core Engine
15 approved
pChEMBL 10.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Peroxisome proliferator-activated receptor alpha matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q07869, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why type 2 diabetes mellitus is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5004
Total Compounds
1100
Total Assays
15
Approved Drugs
IC50: 1303.0, KI: 209.0, EC50: 4242.0, KD: 39.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1813003
|
10.6 | EC50 | — |
|
|
No preferred name
CHEMBL468160
|
10.5 | EC50 | — |
|
|
No preferred name
CHEMBL21241
|
10.3 | Ki | — |
|
|
No preferred name
CHEMBL481551
|
10.1 | EC50 | — |
|
|
No preferred name
CHEMBL513145
|
10.1 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ELAFIBRANOR
CHEMBL3707395
|
2024 |
|
|
PEMAFIBRATE
CHEMBL247951
|
2017 |
|
|
ROSIGLITAZONE
CHEMBL121
|
1999 |
|
|
FENOFIBRATE
CHEMBL672
|
1993 |
|
|
CIPROFIBRATE
CHEMBL557555
|
1985 |
|
|
BERBERINE
CHEMBL295124
|
— |
Source Header